Project
Clostridioides difficile infection: can diagnosis, treatment and management be optimised?
Apr 30, 2024
Challenges and improvement opportunities for Faecal Microbiota Transplantation in the treatment of recurrent Clostridioides difficile infection in Canada
Research SummaryPublished Sep 30, 2024
In this video, Dr. Dina Kao, gastroenterologist and professor at the University of Alberta, discusses the challenges for the use of Faecal Microbiota Transplantation in the treatment of recurrent C. difficile infection in Canada.
Related Content
Topics
Document Details
- Copyright: Ferring Pharmaceuticals
- Publisher: RAND Corporation
- Availability: Web-Only
- Year: 2024
- DOI: https://doi.org/10.7249/RBA3265-4
- Document Number: RB-A3265-4
Citation
RAND Style Manual
Chicago Manual of Style
Kao, Dina, Challenges and improvement opportunities for Faecal Microbiota Transplantation in the treatment of recurrent Clostridioides difficile infection in Canada, RAND Corporation, RB-A3265-4, 2024. As of October 13, 2024: https://www.rand.org/pubs/research_briefs/RBA3265-4.html
Kao, Dina, Challenges and improvement opportunities for Faecal Microbiota Transplantation in the treatment of recurrent Clostridioides difficile infection in Canada. Santa Monica, CA: RAND Corporation, 2024. https://www.rand.org/pubs/research_briefs/RBA3265-4.html.
Research conducted by
This publication is part of the RAND research brief series. Research briefs present policy-oriented summaries of individual published, peer-reviewed documents or of a body of published work.
RAND is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.